Protara Therapeutics provided a business update, stating that the interim analysis for the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients is on track for 4Q 2025. They are also expected to present interim analysis for the ADVANCED-2 trial of TARA-002 in NMIBC patients in 1Q 2026.
Cash, cash equivalents, and investments for Protara are around $134 million as of September 30, 2025, supporting planned operations into mid-2027. Protara has made significant advancements in their clinical programs this year and remains focused on transformative therapies for cancer and rare diseases.
The company anticipates providing an update on discussions with the FDA regarding BCG-Naïve opportunities in 4Q 2025. They are exploring subcutaneous dosing with intravesical dosing and combination treatments with TARA-002 in NMIBC patients with CIS. Protara is working on the Phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with LMs.
Protara expects to begin dosing in the THRIVE-3 trial, a registrational Phase 3 clinical trial of IV Choline Chloride by the end of 2025. They are facing administrative and funding challenges but remain on track for future milestones. The company was recognized among BioSpace’s Best Places to Work in November 2025.
Protara’s TARA-002 is an investigational cell therapy for NMIBC and LMs, granted Rare Pediatric Disease Designation by the FDA. TARA-002 activates immune cells and triggers a pro-inflammatory response, enhancing the antitumor immune response. Bladder cancer is the 6th most common cancer in the US, with NMIBC representing 80% of diagnoses. LMs are rare congenital malformations of lymphatic vessels. IV Choline Chloride is being developed as an investigational therapy for patients on parenteral support. It aims to address choline deficiency, which affects approximately 78% of patients dependent on parenteral support. Protara Therapeutics, the company behind IV Choline Chloride, is also working on TARA-002, a cell-based therapy for bladder cancer and lymphatic malformations. The company recently released its financial statements, showing total assets of $144,636 and total stockholders’ equity of $132,291. 1. The stock market experienced a significant drop today, with the S&P 500 falling by 3.5%. This is the largest single-day decline in over a year, attributed to concerns over rising inflation and interest rates.
2. The latest unemployment report shows a decrease in jobless claims, with 200,000 fewer claims filed last week. This is a positive sign for the economy as businesses continue to reopen and hire more workers.
3. The CDC announced that fully vaccinated individuals no longer need to wear masks or social distance in most indoor and outdoor settings. This comes as a relief to many Americans who have been waiting for guidance on post-vaccination activities.
4. Tesla reported record-breaking profits in the first quarter of 2021, with $438 million in net income. The electric car company also saw a 74% increase in revenue, driven by strong demand for their vehicles.
5. The housing market remains hot, with home prices increasing by 12% compared to last year. Low mortgage rates and a shortage of inventory are fueling competition among buyers, leading to bidding wars and quick sales.
Read more at GlobeNewswire.: Protara Therapeutics Announces Third Quarter 2025 Financial